XML 52 R34.htm IDEA: XBRL DOCUMENT

Redeemable Non-Controlling Interests	12 Months Ended
Redeemable Non-Controlling Interests	Dec. 31, 2024
Redeemable Non Controlling Interests [Abstract]
Redeemable Non-Controlling Interests	NOTE 22— Redeemable Non-Controlling Interests: In December 2024, Teva entered into an agreement with JKI Co., Ltd. (“JKI”) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. (“J-Will”), through which JKI will acquire Teva-Takeda, Teva’s business venture in Japan (the “BV”), which includes generic products and legacy products. Since the establishment of the BV and as of December 31, 2024, Teva holds 51 % of the outstanding common stock of the BV, therefore consolidating the BV in its financial statements. Pursuant to existing agreements with the minority investors of the BV, a redemption feature exists whereby the interest held by the minority investors is redeemable as a result of a sale of the BV, subject to certain terms listed therein. The redemption value would be determined based on a prescribed formula derived from the consideration received from the sale of the BV. The balance of the redeemable non-controlling interest is reported at the greater of the initial carrying amount adjusted for the redeemable non-controlling interest’s share of earnings or losses and other comprehensive income or loss, or its estimated redemption value. The resulting changes in the estimated redemption amount (increases or decreases) are recorded with corresponding adjustments against retained earnings or, in the absence of retained earnings, additional paid-in-capital. Since the share redemption feature does not include a share cap, these interests are presented on the consolidated balance sheets outside of permanent equity under the caption “Redeemable non-controlling interest”. As of December 31, 2024, the total balance of the redeemable non-controlling interests is $340 million.